APOE and depressive symptom measurement: Previous studies have evaluated the effects of disclosing APOE genotype and amyloid imaging results to cognitively healthy participants and found there was no increase in psychological distress, anxiety, or depression (Green et al., 2009; Grill et al., 2020).